CN205215764U - Malleation capsule - Google Patents
Malleation capsule Download PDFInfo
- Publication number
- CN205215764U CN205215764U CN201520602260.6U CN201520602260U CN205215764U CN 205215764 U CN205215764 U CN 205215764U CN 201520602260 U CN201520602260 U CN 201520602260U CN 205215764 U CN205215764 U CN 205215764U
- Authority
- CN
- China
- Prior art keywords
- capsule
- malleation
- gelatin
- capsule according
- bubble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 128
- 229920000159 gelatin Polymers 0.000 claims abstract description 31
- 235000019322 gelatine Nutrition 0.000 claims abstract description 31
- 108010010803 Gelatin Proteins 0.000 claims abstract description 30
- 239000008273 gelatin Substances 0.000 claims abstract description 30
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 30
- 239000007789 gas Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 7
- 238000007385 chemical modification Methods 0.000 claims description 6
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003605 opacifier Substances 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 235000013772 propylene glycol Nutrition 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical group CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 241001428166 Eucheuma Species 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000013736 caramel Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 34
- 239000002994 raw material Substances 0.000 abstract description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920001875 Ebonite Polymers 0.000 abstract 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 11
- 238000010586 diagram Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000012120 mounting media Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001466460 Alveolata Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model relates to a malleation capsule, a serial communication port, include: the body, it is the cavity form, the filler, it packs in this internally, the bubble, it sets up in this internally, just the atmospheric pressure of bubble is greater than an atmospheric pressure. This malleation capsule's characteristic is for the driving fit seam and can fill medicine such as liquid powder, and this capsule can be for the ebonite bag, and the raw materials can be for gelatin (gelatin) or hydroxypropyl methyl cellulose (HPMC).
Description
Technical field
This utility model relates to a kind of malleation capsule, and this malleation capsule can be accelerated to destroy capsule and forms cut and accelerate drug release, and the feature of this capsule is containing gas in seal capsule, and internal pressure is malleation.
Background technology
Capsule is that one develops pharmaceutical dosage form rapidly, thickness is approximately 0.1-0.7 millimeter, be widely applied to the endo-medicine such as medicine, health food, have convenient to preserve, dosage accurately, can the advantage such as Drug controlled release, and bad smell, the maintenance pharmaceutically active of active constituents of medicine can be covered, therefore, user is easy to accept.
Medicine can be sealed in capsule by capsule formulation, due to the feature of its sealing, the medicine in capsule can avoid because of with outside air, contact with moisture and reduce activity or make moist, therefore, it is possible to maintain a long-term stability.
Some active medicinal matter may have the biopharmacy or the physicochemical properties that make it be difficult to be mixed with commercial acceptable formula.But such material can with liquid carrier medium form administration.The potentiality that 1,2-PD (1,2-propanediol) and dimethyl isosorbite ester (dimethylisosorbide) are used for such mounting medium as solvent are very large.The composition of mounting medium can make these solvents form emulsion under one's belt, thus promotes the absorption of active medicinal matter.Mounting medium must be prepared exactly, thus makes it not have an impact to ingredient, and can not destroy its useful character.The solubilization of pharmaceutical carrier may change active substance character and make it Shen Dian, causes patient medication quantity not sufficient.Emulsifying (emulsifying) character of pharmaceutical carrier also can change, and may not form emulsion (emulsion) under one's belt during administration, and in addition, pharmaceutically active substances can not correctly be absorbed.
This liquid formulations is encapsulated in capsule and provides one medication very easily for this active medicinal matter.But the capsule product of commercial acceptable filling liquid is also attended by the difficulty limiting this approach availability.
Capsule for medicine can be divided into rigid capsule and soft capsule two class, wherein, rigid capsule (hereinafter referred to as hard capsule) can fill the solid-state drug such as medicated powder or fine grained medicine, and soft capsule (hereinafter referred to as soft capsule) can fill the liquid drugs such as liquid medicine.
Capsule raw material can be gelatin (gelatin), sorbitol (sorbital), hydroxypropyl emthylcellulose (hydroxypropylmethylcellulose, HPMC is made in abbreviation) and opaque food coloring or other additive.
It is gelatin (gelatin) that conventional capsules manufactures raw material, protein or victory peptide is extracted in animal cuticle, bone or connective tissue, this protein or victory peptide include collagen (collagen), then, the flaxen protein layer of hydrophilic obtained after protein or victory peptide being boiled in water, is gelatin.
In addition, the capsule raw material of frequent use can be hydroxypropyl emthylcellulose, namely, hypromellose (hydroxypropylmethylcellulose, be abbreviated as HPMC), it is a kind of polymer with stickiness, is commonly used in oral drugs the succedaneum serving as excipient, emulsifying agent, thickening agent, suspending agent or gelatin.After cellulose alkali treatment, the alcoxyl anion that hydroxyl deprotonation generates can carry out addition to expoxy propane, generates hydroxypropylcelluloether ether; Also can with chloromethanes condensation, generate methyl cellulose ether.When two kinds of reactions are carried out simultaneously, just hydroxypropyl emthylcellulose can be produced.
Separately there is the substitute of multiple capsule raw material, comprise the extract of Sargassum, i.e. polysaccharide colloid, this vegetable raw material can avoid the animal protein generation cross-linking reaction included with capsule, the intensity of capsule utricule can be maintained, further, because the popular of U.S.'s bovine spongiform encephalopathy gradually rises in recent years, improvement soft capsule raw material comes into one's own gradually.Other alternative materials, as agaropectin, water solublity etherificate starch derivatives, HPMC, i.e. carrageenin etc., also has market share gradually.
One of them object of capsule improvement is improve the bioavailability of pharmacological agents.Active component can when capsules break, rapid release in liquid form.With lozenge composition unlike, active component be allowed to become absorbable state, not need the complete disintegrate of capsule.Meanwhile, in comparison, insoluble active component may be interspersed within liquid carrier, can impel absorption faster, as the solution of hydrophobic drug in hydrophilic solvent; In Digestion, capsule can break under one's belt, and hydrophobic drug may be interspersed among gastric juice.
But capsule has slow phenomenon to be common problem in the process of disintegrate, research thinks that capsule disintegrates is slow mainly because gelatin produces caused by cross-linking reaction.Aldehyde radical is formed because oxidation easily occurs aminoacid in gelatin molecule, formed aldehyde radical can with the cross-linking reaction of aminoacid generation around, thus form the intra/inter-tridimensional network interconnected of molecule, cause the increase of gelatine molecular weight, structural stability, water solublity decline, cause the prolonged disintegration of capsule.For the problem of capsule disintegrates, main solution has: 1. add antioxidant, 2. adjust capsule formula and change composition such as water, plasticizer equal proportion, 3. adopt comparatively be not easy be oxidized raw material.
Utility model content
For solving above-mentioned capsule not easy disintegrating and affect the problem of the bioavailability of medicine in gastric juice, the inventor of utility model takes a lot of trouble conception research and development and obtains this utility model content.
In order to reach the object of above-mentioned utility model, this utility model provides a kind of malleation capsule, the characteristic that high malleation capsule utilizes capsule pressure to be malleation, after taking, accelerate capsule destroy in stomach and the speed of disintegrate, and then accelerate the release of medicine, be beneficial to drug absorption, utilize by organism.
Malleation capsule of the present utility model comprises: body, and it is hollow form; Implant, it is filled in body; Bubble, it is arranged in body, and the air pressure of described bubble is greater than an atmospheric pressure.
Wherein, this capsule can be seal capsule.
Wherein, this capsule pressure must be malleation, and is greater than an atmospheric pressure.
Wherein, this capsule contains gas, and this gas can be the mist of oxygen, helium, nitrogen or carbon dioxide or above-mentioned gas or gas not aitiogenic with content.
Wherein, this capsule raw material can be gelatin, namely results from the hydrolysate of animality collagen protein.
Wherein, this capsule raw material can be hypromellose (hydroxypropylmethylcellulose, HPMC).
Wherein, this capsule raw material can also comprise Eucheuma gelatinosum, starch, alginic acid, guar gum (guargum), and the additive such as pharmaceutically acceptable opacifier, plasticizer.
Wherein, this gelatin can be alkaline-process gelatin, acid process gelatin or chemical modification (chemicalmodification) gelatin etc.
Wherein, this plasticizer is selected from the group be made up of following material: glycerol, Sorbitol, maltose, glucose, polysaccharide, sucrose, xylitol, mannitol, propylene glycol, Polyethylene Glycol.
Wherein, the group that forms of the following material of the optional freedom of this opacifier: caramel, titanium oxide, ferrum oxide.
Wherein, the implant of this capsule can be medicine or the health food such as aqueous, suspension, pasty state, Powdered, graininess.
Wherein, the shape of this capsule can be ball-type, ellipse, long ellipse, test-tube type or angle-style.
In order to reach the object of above-mentioned utility model, this utility model provides a kind of malleation capsule, and this malleation capsule can by following methods manufacture: filled capsules under positive pressure environment, then seals this capsule, wherein retain bubble in capsule, this capsule finished product is malleation capsule under an atmospheric pressure environment.
In order to reach the object of above-mentioned utility model, this utility model also provides a kind of malleation capsule, this malleation capsule can by following methods manufacture: fill in low temperature environment, above-mentioned low temperature environment is lower than 25 DEG C, seal this capsule again, wherein retain bubble in capsule, this capsule finished product is malleation capsule under normal temperature environment.
Accompanying drawing explanation
Fig. 1 is malleation capsule schematic diagram of the present utility model.
Fig. 2 is another schematic diagram of malleation capsule of the present utility model.
Fig. 3 A is the schematic diagram of malleation capsule of the present utility model when not yet digesting in stomach after taking.
Fig. 3 B is the schematic diagram of malleation capsule of the present utility model when digesting in stomach after taking.
[description of reference numerals]
1: capsule utricule; 2: the barotropic gas contained in capsule or bubble; 3: capsule utricule closing line; 5: the medicine that capsule is filled.
Detailed description of the invention
All technical and scientific terminology described in this description, unless defined to some extent in addition, is all the meaning that this those skilled in the art can understand jointly.This utility model is explained by the following examples, but this utility model does not limit by following embodiment.This utility model material used is all the material being easy to obtain that market is sold, and it can be obtained by the method shown in following example.
The purpose of this utility model is to provide a kind of manufacture method of malleation capsule, and the method comprises the following steps:
Step 1: the environment of filled capsules is placed in positive pressure environment or low temperature environment;
Step 2: medicine is filled and puts in capsule, and retain the alveolate space of inner tool;
Step 3: seal capsule utricule, makes its surface without any opening, avoids gas leak.
Above-mentioned positive pressure environment refers to and is greater than an atmospheric environment, and namely an atmospheric pressure is equal to International System of Units 1atm, 1013hPa or 76cm-Hg.
About above-mentioned bubble, this bubble not affect dosage for principle, and without the need to being particularly limited to Air Bubble Size; This gas can be the gas not affecting medicine, content.
Above-mentioned low temperature environment is lower than 25 DEG C.
About above-mentioned malleation capsule, its shape can be ball-type, ellipse, long ellipse, test-tube type, angle-style etc.; Its size is not particularly limited, that is, content amount can be adjusted to the scope of about 1 milligram to 10 grams.
Even if capsule raw material of the present utility model is after a kind of drying, still there is the material of the character of reversible gel (reversiblegelling).This material such as formed by material in the glue such as HPMC, gelatin, Eucheuma gelatinosum, starch, alginic acid, guar gum (guargum), and, come better as the raw material of capsule with the material including gelatin or HPMC and plasticizer.In addition, capsule raw material can include the additives such as opacifier as required.
Above-mentioned gelatin can to use by the animal such as cattle, pig obtain, collagen protein gone out through hydrolysis extraction and the gelatin obtained.Further, as the gelatin with above-mentioned reversible gel character, it comprises the gelatin etc. obtained by alkaline process, acid system or chemical modification (chemicalmodification).Making gelatin at use acid system is that hydrolytic reagent uses the acids such as hydrochloric acid or sulphuric acid; When using alkaline process to make gelatin, hydrolytic reagent uses the bases such as Calx; Chemical modification gelatin is the material by obtaining after the amido of gelatin and the organic acid reaction such as succinic acid (succinicacid) or phthalic acid (phthalicacid).
Above-mentioned plasticizer can comprise glycerol, Sorbitol, maltose, glucose, polysaccharide, sucrose, xylitol, mannitol, propylene glycol, Polyethylene Glycol etc., but, be not limited thereto.
Above-mentioned opacifier can comprise caramel, titanium oxide, ferrum oxide etc., but, be not limited thereto.
The form that this utility model is applicable to capsule filling is not particularly limited, and it can be aqueous, suspension, pasty state, Powdered, graininess etc.
The thickness of hard capsule of the present utility model only needs the function that can play capsule, and there is no particular restriction, but is good with 0.01-5 millimeter (mm) thickness, and preferred thickness is 0.05-1mm.
Capsule of the present utility model can be used for the purposes such as pharmaceuticals, accurate pharmaceuticals, food, cosmetics, can determine according to the composition of implant.
About above-mentioned pharmaceuticals, accurate pharmaceuticals, if the active ingredient being filled in capsule of the present utility model does not undermine capsule machine able one, without particular determination.Drug class is including, but not limited to the following vitamins enumerated, antipyretic, analgesics, antiinflammatory, antiulcer agent, cardiac tonic, anticoagulant, hemorrhage, anti-bone reabsorption agent, angiogenesis inhibiting agent, anti-strongly fragrant dose, antitumor agent, antitussive stops expectorant agent, slow dose of muscle, Anti-epileptics, anti-allergic agent, arrhythmia therapeutic agent, vasodilation, antihypertensive diuretic agent, Remedies for diabetes, tuberculosis, hormone preparation, analgesic, antibacterial agent, antifungal and antiviral agent etc., but be not defined in above-mentioned pharmacological action group, comprise the object that all active ingredient poor to water relative solubility are this utility model hard capsule.Be preferably the active substance of insoluble.
Malleation capsule schematic diagram simultaneously with reference to Fig. 1, Fig. 2 is described this utility model preferred embodiment.
Embodiment one
Malleation capsule manufacture method provided by the utility model comprises the following step:
Step 1: under filled capsules environment is placed in positive pressure, this positive pressure need be greater than an atmospheric pressure;
Step 2: under positive pressure environment, is filled in capsule by medicine 5;
Step 3: seal capsule utricule 1, makes its surface without any opening, avoids gas leak, but in wherein retaining bubble 2;
Step 4: capsule finished product is placed on home, namely under an atmospheric pressure environment, the pressure of capsule can be greater than an atmospheric pressure, thus is formed as malleation capsule.
This malleation capsule above-mentioned before the seal capsule utricule 1 or simultaneously, can another injecting gas, makes wherein air chamber be the gas 2 of injection, then is sealed.
This malleation capsule, after user takes, when entering gastric digestion, when capsule disintegrates is to time to a certain degree, when wherein malleation is enough to break through capsule formation cut, can reach the object (Fig. 3 A, Fig. 3 B) of release medicine 5.
Embodiment two
Malleation capsule manufacture method provided by the utility model comprises the following step:
Step 1: under filled capsules environment is placed in cryogenic conditions, this cryogenic conditions need lower than 25 DEG C;
Step 2: under low temperature environment, is filled in capsule by medicine 5;
Step 3: seal capsule utricule 1, makes its surface without any opening, avoids gas leak, but in wherein retaining bubble 2;
Step 4: capsule finished product is placed on home, namely under room temperature environment, the pressure of capsule can be greater than an atmospheric pressure, thus is formed as malleation capsule.
This malleation capsule above-mentioned, can another injecting gas when seal capsule utricule 1, makes wherein air chamber be the gas 2 injected, then is sealed.
This malleation capsule is after user takes, when entering gastric digestion, glue intraluminal pressure is further supercharging because of body temperature, when capsule disintegrates is to time to a certain degree, when wherein malleation is enough to break through capsule formation cut, the object (Fig. 3 A, Fig. 3 B) of release medicine 5 can be reached.
This capsule is the capsule of sealing, this capsule must be closely sealed utricule 1, the closely sealed juncture of capsule can for utilizing the mode of the capsule utricule bonding land 4 shown in the capsule utricule closing line 3 shown in Fig. 1 or Fig. 2, closely sealed region is formed after melting as this bonding land of a part for capsule utricule, but, this utility model is not limited to the mode engaging and become seal capsule, and the object of schematic diagram is only and illustrates that malleation capsule of the present utility model must for closely sealed capsule.
Above possible embodiments of the present utility model is illustrated, this embodiment is also not used to limit technical scope of the present utility model, and all equivalences not departing from this utility model purport and spirit are implemented or change all should be contained in technical scope of the present utility model.
The novelty that above-mentioned multinomial effect fully meets the legal requirements and progressive, file an application in accordance with the law, earnestly asks your office and check and approve this utility model application case, to encourage innovation and creation.
Claims (9)
1. a malleation capsule, is characterized in that, comprising:
Body, it is hollow form;
Implant, it is filled in body;
Bubble, it is arranged in body, and the air pressure of described bubble is greater than an atmospheric pressure.
2. malleation capsule according to claim 1, is characterized in that,
Described capsule can be ball-type, ellipse, test-tube type or angle-style.
3. malleation capsule according to claim 1, is characterized in that,
The gas of described bubble can be oxygen, helium, nitrogen or carbon dioxide.
4. malleation capsule according to claim 1, is characterized in that,
The body material of described capsule is gelatin or hydroxypropyl emthylcellulose.
5. malleation capsule according to claim 1, is characterized in that,
The bulk stock of described capsule also comprises Eucheuma gelatinosum, starch, alginic acid or guar gum, or additive, and this additive comprises pharmaceutically acceptable plasticizer, opacifier.
6. malleation capsule according to claim 4, is characterized in that,
Described gelatin is alkaline-process gelatin, acid process gelatin or chemical modification gelatin.
7. malleation capsule according to claim 5, is characterized in that,
Described plasticizer is glycerol, Sorbitol, maltose, glucose, polysaccharide, sucrose, xylitol, mannitol, propylene glycol or Polyethylene Glycol.
8. malleation capsule according to claim 5, is characterized in that,
Described opacifier is caramel, titanium oxide or ferrum oxide.
9. malleation capsule according to claim 1, is characterized in that,
Described implant is medical composition or health food, and described medical composition or health food can be aqueous, suspension, pasty state, Powdered, graininess.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520602260.6U CN205215764U (en) | 2015-08-11 | 2015-08-11 | Malleation capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520602260.6U CN205215764U (en) | 2015-08-11 | 2015-08-11 | Malleation capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205215764U true CN205215764U (en) | 2016-05-11 |
Family
ID=55890863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520602260.6U Expired - Fee Related CN205215764U (en) | 2015-08-11 | 2015-08-11 | Malleation capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205215764U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI681726B (en) * | 2018-09-14 | 2020-01-11 | 大陸商雲南中煙工業有限責任公司 | Method for manufacturing outer container with water-insoluble film-sealing capsule |
-
2015
- 2015-08-11 CN CN201520602260.6U patent/CN205215764U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI681726B (en) * | 2018-09-14 | 2020-01-11 | 大陸商雲南中煙工業有限責任公司 | Method for manufacturing outer container with water-insoluble film-sealing capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1832282A1 (en) | Band seal for hard capsule | |
| CN100593398C (en) | Film-shaped, dissolvable preparations for active substance release and method for the production thereof | |
| CN1354656A (en) | Compositions and methods for mucosal delivery | |
| WO1995022962A1 (en) | Controlled release composition | |
| EP1849472A1 (en) | Composition for preparing carbon dioxide preparation for external use | |
| CN103118662A (en) | Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form | |
| JP2006016372A (en) | Enteric hard capsule formulation | |
| CN102133207A (en) | Novel capsule colon-specific drug delivery system (CSDDS) and preparation method thereof | |
| CN106466303A (en) | Malleation capsule and its manufacture method | |
| ZA200402066B (en) | Expandable gastric retention device. | |
| CN104546807A (en) | Olanzapine oral fast dissolving film preparation | |
| CN106074440B (en) | A kind of capsule and preparation method thereof | |
| CN205215764U (en) | Malleation capsule | |
| CN103263402A (en) | Water-drinking-free oral drug composition and preparation method thereof | |
| CN104324016A (en) | Soft-capsule wall material formula | |
| EP3821920A1 (en) | Combination for endoscopic surgery | |
| JP2005526758A (en) | Ibuprofen solution for hard shell capsules | |
| CN106619128A (en) | Sealed storage composition for capsule and sealed storage method thereof | |
| TWI718100B (en) | Positive pressure capsule and manufacturing method thereof | |
| Alexander et al. | Technologies influencing rapidly disintegrating drug delivery systems: A review | |
| CN101011385A (en) | Pharmaceutical composition of coumarin derivative and its preparation and application | |
| TWM511327U (en) | Positive pressure capsule | |
| US20170056319A1 (en) | Positive pressure capsules and method of manufacturing the same | |
| WO2017035747A1 (en) | Positive pressure capsules and method of manufacturing the same | |
| CN104490802B (en) | Rhodioside enteric coatel tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201020 Address after: Hsinchu City, Taiwan, China Patentee after: Yongda medical materials Co.,Ltd. Address before: california Patentee before: Cao Ronghua Patentee before: Wang Tinghua |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160511 |